DR. SHAHIN RAFII, M.D.
Medical Practice in New York, NY
License number
New York 171564
Category
Medical Practice
Type
Specialist
Address
Address
1300 York Ave Weill Cornell Medical College ROOM A-863, New York, NY 10065
Phone
(917) 287-3801
(212) 746-8481 (Fax)
(212) 746-8481 (Fax)
Personal information
See more information about SHAHIN RAFII at radaris.comName
Address
Phone
1320 York Ave APT 21M, New York, NY 10021
1320 York St, New York, NY 10021
1320 York Ave, New York, NY 10021
24 Clover Dr, Great Neck, NY 11021
24 Clover Dr, Great Neck, NY 11021
Organization information
See more information about SHAHIN RAFII at bizstanding.comShahin Rafii MD
New York, NY
Industry:
Internist
Phone:
(212) 746-2920 (Phone), (212) 246-2070 (Phone)
Addresses:
525 E 68 St, New York, NY 10065
252 E 68 St, New York, NY 10065
252 E 68 St, New York, NY 10065
Shahin Rafii
Categories:
Hematology Physicians & Surgeons, Internal Medicine Physicians & Surgeons, Oncology Physicians & Surgeons, ...
Additional:
Physicians & Surgeons
Professional information
See more information about SHAHIN RAFII at trustoria.com
Gpr125 As A Marker For Stem And Progenitor Cells And Methods Use Thereof
Gpr125 As A Marker For Stem And Progenitor Cells And Methods Use Thereof
US Patent:
2010033, Dec 30, 2010
Filed:
Oct 23, 2007
Appl. No.:
12/446730
Inventors:
Shahin Rafii - New York NY, US
Sergey V. Shmelkov - New York NY, US
Marco Seandel - New York NY, US
Sai H. Chavala - Durham NC, US
Sergey V. Shmelkov - New York NY, US
Marco Seandel - New York NY, US
Sai H. Chavala - Durham NC, US
Assignee:
CORNELL RESEARCH FOUNDATION, INC. - Ithaca NY
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - New York NY
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - New York NY
International Classification:
A61K 35/12, C12N 5/074, G01N 33/53, A61P 35/00
US Classification:
424 937, 435325, 435352, 435363, 435366, 435351, 435350, 435368, 435371, 435 721
Abstract:
The present invention relates to GPR1 25 as a marker of stem and progenitor cells, including multipotent adult spermatogonial-derived stem cells (MASCs), spermatogonial stem and progenitor cells, skin stem or progenitor cells, intestinal stem or progenitor cells, neural stem or progenitor cells, and cancer stem cells. The invention provides, inter alia, methods for enriching or isolating GPR125-positive stem or progenitor cells, methods for detecting GPR125-positive stem or progenitor cells, methods for culturing GPR125-positive stem or progenitor cells, purified GPR125-positive stem or progenitor cells, therapeutic compositions containing purified GPR125-positive stem or progenitor cells, methods for targeting therapeutic agents to GPR125-positive stem and progenitor cells, and methods of treatment comprising administering GPR125-positive stem and progenitor cells, or differentiated cells derived therefrom, to subjects in need thereof. The present invention also provides methods of detecting cancer cells based on GPR1 25 expression, and methods of targeting therapeutic agents to cancer cells to GPR125-positive cancer cells.
Dr. Shahin Rafii, New York NY - MD (Doctor of Medicine)
Dr. Shahin Rafii, New York NY - MD (Doctor of Medicine)
Specialties:
Hematology, Medical Oncology, Oncology
Address:
NATIONAL COUNCIL ON WOMENS HEALTH INC
1300 York Ave SUITE D601, New York 10065
(212) 746-2070 (Phone), (212) 746-8893 (Fax)
1300 York Ave SUITE D601, New York 10065
(212) 746-2070 (Phone), (212) 746-8893 (Fax)
Certifications:
Hematology, 1992, Internal Medicine, 1989, Medical Oncology, 1991
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Albert Einstein College of Medicine of Yeshiva University
Graduated: 1986
Ny Hosp-Cornell Med Ctr
Albert Einstein College of Medicine of Yeshiva University
Graduated: 1986
Ny Hosp-Cornell Med Ctr
Shahin Rafii, New York NY
Shahin Rafii, New York NY
Specialties:
Hematologist
Address:
1300 York Ave, New York, NY 10065
Methods And Compositions For Promoting Survival And Proliferation Of Endothelial Cells And Stimulating Angiogenesis
Methods And Compositions For Promoting Survival And Proliferation Of Endothelial Cells And Stimulating Angiogenesis
US Patent:
2014004, Feb 13, 2014
Filed:
May 20, 2013
Appl. No.:
13/897829
Inventors:
Shahin RAFII - New York NY, US
Fan ZHANG - Fort Lee NJ, US
Marco SEANDEL - New York NY, US
Fan ZHANG - Fort Lee NJ, US
Marco SEANDEL - New York NY, US
Assignee:
Cornell Research Foundation, Inc. - Ithaca NY
International Classification:
C12N 5/0735, C12N 5/09, C12N 5/0789
US Classification:
435347, 435325, 435366, 435373, 435383, 435404
Abstract:
The present invention relates to adenovirus E4ORF1 gene and to endothelial cells engineered to express the E4ORF1 gene. The present invention also relates to uses of the E4ORF1 gene, and cells expressing the E4ORF1 gene, and to compositions comprising the E4ORF1 gene, or comprising cells expressing the E4ORF1 gene.
Slitrks As Markers For Stem And Progenitor Cells And Methods Of Use Thereof
Slitrks As Markers For Stem And Progenitor Cells And Methods Of Use Thereof
US Patent:
8043803, Oct 25, 2011
Filed:
Dec 6, 2007
Appl. No.:
11/951761
Inventors:
Shahin Rafii - New York NY, US
Till Milde - Roosevelt Island NY, US
Sergey V. Shmelkov - New York NY, US
Till Milde - Roosevelt Island NY, US
Sergey V. Shmelkov - New York NY, US
Assignee:
Cornell Research Foundation, Inc. - Ithaca NY
International Classification:
C12Q 1/68
US Classification:
435 6, 435325
Abstract:
The present invention relates to slitrk proteins as markers of stem and progenitor cells, including embryonic stem cells and hematopoietic stem and progenitor cells, and also as a marker of leukemia and lymphoma cells, and of endothelial cells. The invention provides, inter alia, methods for purifying slitrk-positive cells, methods for detecting slitrk-positive cells, purified preparations of slitrk-positive cells, therapeutic compositions containing purified slitrk-positive cells, methods for targeting therapeutic agents to slitrk-positive cells, and methods of treatment, including but not limited to, methods of administering slitrk-positive cells to subjects in need thereof.
Endothelial Cells Expressing Adenovirus E4Orf1 And Methods Of Use Thereof
Endothelial Cells Expressing Adenovirus E4Orf1 And Methods Of Use Thereof
US Patent:
8465732, Jun 18, 2013
Filed:
Jan 18, 2008
Appl. No.:
12/523372
Inventors:
Shahin Rafii - New York NY, US
Fan Zhang - Fort Lee NJ, US
Marco Seandel - New York NY, US
Fan Zhang - Fort Lee NJ, US
Marco Seandel - New York NY, US
Assignee:
Cornell Research Foundation, Inc. - Ithaca NY
Sloan-Kettering Institute for Cancer Research - New York NY
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
A61K 48/00, C12N 5/00, C12N 15/00
US Classification:
424 9321, 435325, 435455
Abstract:
The present invention relates to adenovirus E4ORF 1 gene and to endothelial cells engineered to express the E40RF 1 gene. The present invention also relates to uses of the E40RF 1 gene, and cells expressing the E40RF1 gene, and to compositions comprising the E4ORF 1 gene, or comprising cells expressing the E4ORF 1 gene.
Methods For Treating Hematopoietic Neoplasms
Methods For Treating Hematopoietic Neoplasms
US Patent:
2009026, Oct 22, 2009
Filed:
Nov 21, 2008
Appl. No.:
12/276064
Inventors:
David CHAPLIN - Watlington, GB
Shahin RAFII - New York NY, US
Shahin RAFII - New York NY, US
International Classification:
A61K 31/7076, A61K 31/661, A61K 31/7064, A61P 35/00
US Classification:
514 45, 514130, 514114, 514 49, 514110
Abstract:
This invention relates to methods for treating, preventing and/or managing hematopoietic neoplasm in a subject by administering to the subject combretastatin A-4 phosphate, or a pharmaceutically acceptable salt thereof. The method may further comprise co-administering a chemotherapeutic agent.
Methods For Organ Regeneration
Methods For Organ Regeneration
US Patent:
2013022, Aug 29, 2013
Filed:
Nov 9, 2011
Appl. No.:
13/884484
Inventors:
Shahin Rafii - New York NY, US
Sina Y. Rabbany - Great Neck NY, US
Sina Y. Rabbany - Great Neck NY, US
Assignee:
CORNELL UNIVERSITY - Ithaca NY
International Classification:
A61K 38/18, A61K 35/12
US Classification:
424 937, 435347, 435325
Abstract:
A method of enhancing or initiating regeneration of an organ in a subject in need thereof comprising the administration of endothelial cells specific to said organ, or inductive endothelial cells specific to said organ, into the area of the body in which organ regeneration is desired in said subject.